{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Kamm K"],"funding":["Universitätsklinik München"],"pubmed_abstract":["<h4>Background</h4>Cluster headache (CH) is a severe, highly disabling primary headache disorder. However, there is little research on CH-related disability, and most of it is based on non CH-specific questionnaires. The aim of this study was to develop a short, CH-specific disability questionnaire.<h4>Methods</h4>The 8-item Cluster Headache Impact Questionnaire (CHIQ) was developed based on a literature review and patient and expert interviews. The questionnaire was tested in 254 CH patients (171 males; 47.5 ± 11.4 years; 111 chronic CH, 85 active episodic CH, 52 episodic CH in remission) from our tertiary headache center or from a German support group.<h4>Results</h4>Reliability and validity of the CHIQ was evaluated in active episodic and chronic CH patients (n = 196). Internal consiste"],"journal":["The journal of headache and pain"],"pagination":["37"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8932058"],"repository":["biostudies-literature"],"pubmed_title":["Cluster Headache Impact Questionnaire (CHIQ) - a short measure of cluster headache related disability."],"pmcid":["PMC8932058"],"pubmed_authors":["Kamm K","Ruscheweyh R","Straube A"],"additional_accession":[]},"is_claimable":false,"name":"Cluster Headache Impact Questionnaire (CHIQ) - a short measure of cluster headache related disability.","description":"<h4>Background</h4>Cluster headache (CH) is a severe, highly disabling primary headache disorder. However, there is little research on CH-related disability, and most of it is based on non CH-specific questionnaires. The aim of this study was to develop a short, CH-specific disability questionnaire.<h4>Methods</h4>The 8-item Cluster Headache Impact Questionnaire (CHIQ) was developed based on a literature review and patient and expert interviews. The questionnaire was tested in 254 CH patients (171 males; 47.5 ± 11.4 years; 111 chronic CH, 85 active episodic CH, 52 episodic CH in remission) from our tertiary headache center or from a German support group.<h4>Results</h4>Reliability and validity of the CHIQ was evaluated in active episodic and chronic CH patients (n = 196). Internal consiste","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-26T04:35:06.147Z","creation":"2025-02-19T03:47:08.104Z"},"accession":"S-EPMC8932058","cross_references":{"pubmed":["35303796"],"doi":["10.1186/s10194-022-01406-y"]}}